ZURICH (Reuters) -Novartis said on Tuesday a previously announced restructuring programme could lead to 8,000 jobs being cut, including up to 1,400 in Switzerland, confirming a report by Swiss newspaper TagesAnzeiger. Novartis said in an emailed statement it had made good progress in implementing its new organisational structure that involved integrating its pharmaceuticals and oncology business units and would lead to eliminating roles across the organisation. "This restructuring could potentially impact 1,400 positions based in Switzerland, out of around 8,000 positions impacted globally," the company said, adding it had currently 108,000 employees globally, including 11,600 in Switzerland.
Today's Research Daily features preview of the Q2 earnings season and new research reports for J&J (JNJ), AMD (AMD), and Union Pacific (UNP).
The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.